High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
暂无分享，去创建一个
W. Klapper | F. Jardin | E. Hoster | G. Salles | F. Berger | O. Casasnovas | P. Feugier | E. Macintyre | C. Pott | C. Haioun | M. Dreyling | O. Hermine | V. Ribrag | M. Unterhalt | C. Thieblemont | J. Brière | M. Delfau-Larue